NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $3.13 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.12 0.00 (-0.16%) As of 05/22/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Esperion Therapeutics Stock (NASDAQ:ESPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Esperion Therapeutics alerts:Sign Up Key Stats Today's Range$3.12▼$3.1450-Day Range$1.91▼$3.1552-Week Range$0.76▼$4.18Volume6.70 million shsAverage Volume21.26 million shsMarket Capitalization$805.76 millionP/E RatioN/ADividend YieldN/APrice Target$5.54Consensus RatingHold Company Overview Esperion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant. The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S. Food and Drug Administration, and NILEMDO (bempedoic acid/ezetimibe), an oral fixed-dose combination therapy. Both products are indicated as adjuncts to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Esperion continues to explore additional formulations and indications for its ACL inhibition platform, with clinical programs aimed at expanding patient access and optimizing long-term cardiovascular outcomes. Headquartered in Ann Arbor, Michigan, Esperion was re-established in 2013 following the acquisition of specific cardiovascular assets from a global pharmaceutical company. The company completed its initial public offering on the NASDAQ Global Market under the ticker symbol “ESPR” and maintains research, development and commercial operations in the United States. Esperion has also pursued regulatory approvals and market launches in Europe, working to broaden its geographic footprint and engage with healthcare providers and payers worldwide. Esperion’s leadership team is led by President and Chief Executive Officer Timothy M. Mayleben, who brings extensive experience in commercial strategy and product launches within the cardiovascular therapeutic area. Under this leadership, the company aims to further develop its pipeline, enhance patient outreach and drive adoption of oral LDL-C–lowering treatments to address the significant unmet needs in cardiovascular health management.AI Generated. May Contain Errors. Read More Esperion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreESPR MarketRank™: Esperion Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 345th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 6 hold ratings, and 1 sell rating.Upside PotentialEsperion Therapeutics has a consensus price target of $5.54, representing about 77.0% upside from its current price of $3.13.Amount of Analyst CoverageEsperion Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Esperion Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth340.00% Earnings GrowthEarnings for Esperion Therapeutics are expected to grow by 340.00% in the coming year, from $0.05 to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -52.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -52.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioEsperion Therapeutics has a PEG Ratio of 2.54. PEG Ratios above 1 indicate that a company could be overvalued.Read more about Esperion Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.40% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 5.18.Change versus previous monthShort interest in Esperion Therapeutics has recently increased by 14.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest9 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,821.00 in company stock.Percentage Held by Insiders1.60% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESPR Stock News HeadlinesEpilogue On Esperion Therapeutics (Rating Downgrade)May 16, 2026 | seekingalpha.comEsperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97May 15, 2026 | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 14, 2026 | globenewswire.comEsperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026May 13, 2026 | globenewswire.comEsperion (ESPR) was downgraded to a Hold Rating at NeedhamMay 5, 2026 | theglobeandmail.com$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKCMay 5, 2026 | globenewswire.comNeedham downgrades Esperion Therapeutics (ESPR)May 5, 2026 | msn.comSee More Headlines ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $3.70 at the beginning of the year. Since then, ESPR shares have decreased by 15.4% and is now trading at $3.13. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) issued its quarterly earnings results on Friday, May, 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.08. The biopharmaceutical company had revenue of $80.10 million for the quarter, compared to analyst estimates of $84.52 million. Esperion Therapeutics had a negative trailing twelve-month return on equity of 0.14% and a net margin of 0.12%. When did Esperion Therapeutics IPO? Esperion Therapeutics (ESPR) raised $70 million in an initial public offering (IPO) on Wednesday, June 26th 2013. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. Who are Esperion Therapeutics' major shareholders? Top institutional shareholders of Esperion Therapeutics include Wasatch Advisors LP (6.13%), Orbimed Advisors LLC (4.11%), AIGH Capital Management LLC (1.71%) and Eversept Partners LP (0.67%). Insiders that own company stock include Benjamin Halladay, Benjamin Looker and Eric Warren. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY). Company Calendar Last Earnings5/08/2026Today5/24/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, ESPR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees200Year Founded2008Price Target and Rating Average Price Target for Esperion Therapeutics$5.54 High Price Target$9.00 Low Price Target$3.16 Potential Upside/Downside+77.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E Ratio62.60 P/E Growth2.54Net Income-$22.68 million Net Margins0.12% Pretax Margin-1.33% Return on Equity-0.14% Return on Assets0.12% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.18 Sales & Book Value Annual Sales$403.14 million Price / Sales2.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.20) per share Price / Book-2.61Miscellaneous Outstanding Shares257,430,000Free Float253,313,000Market Cap$805.76 million OptionableOptionable Beta0.91 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ESPR) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
